BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Study Summary

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.

Conditions

Solid Tumor, Adult Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms Endometrial Cancer Peritoneal Cancer Solid Tumor

Interventions / Drugs

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment50 participants

Primary Completion—

Lead SponsorBio-Path Holdings, Inc.

Data Retrieved2026-04-11 04:08:24.860962+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.